Patents by Inventor Denise Lew

Denise Lew has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ERK1/2 AND EGFR INHIBITORS COMBINATION THERAPY
    Publication number: 20240307392
    Abstract: The present disclosure relates generally to the use of an ERK1/2 inhibitor in combination with a EGFR inhibitor for treating cancer, specifically solid tumors. The present disclosure also relates to the use of an ERK 1/2 inhibitor in combination with a EGFR inhibitor and a BRAF inhibitor for treating cancer, specifically solid tumors.
    Type: Application
    Filed: June 23, 2022
    Publication date: September 19, 2024
    Inventors: Robert Field SHOEMAKER, Erin Denise LEW, Wei LIN, Leslie Harris BRAIL, Leenus MARTIN, Jingchuan ZHANG, Joanne OH
  • ERK1/2 AND SHP2 INHIBITORS COMBINATION THERAPY
    Publication number: 20240299388
    Abstract: The present disclosure relates generally to the use an ERK1/2 inhibitor in combination with a SHP2 inhibitor for treating cancer, specifically solid tumors.
    Type: Application
    Filed: June 23, 2022
    Publication date: September 12, 2024
    Inventors: Robert Field SHOEMAKER, Erin Denise LEW, Wei LIN, Leslie Harris BRAIL, Leenus MARTIN, Jingchuan ZHANG, Joanne OH
  • ERK1/2 OR SHP2 INHIBITORS AND FLT3 INHIBITORS COMBINATION THERAPY
    Publication number: 20240285624
    Abstract: The present disclosure relates generally to the use of an ERK1/2 inhibitor or a SHP2 inhibitor in combination with a FLT3 inhibitor, such as gilteritinib, for treating cancer, specifically acute myeloid leukemia (AML).
    Type: Application
    Filed: June 23, 2022
    Publication date: August 29, 2024
    Inventors: Robert Field SHOEMAKER, Wei LIN, Erin Denise LEW, Jingchuan ZHANG, Joanne OH, Leenus MARTIN, Leslie Harris BRAIL
  • ERK1/2 AND KRAS G12C INHIBITORS COMBINATION THERAPY
    Publication number: 20240285625
    Abstract: The present disclosure relates generally to the use of an ERK 1/2 inhibitor in combination with a KRAS G12C inhibitor for treating cancer, specifically solid tumors.
    Type: Application
    Filed: June 23, 2022
    Publication date: August 29, 2024
    Inventors: Robert Field SHOEMAKER, Erin Denise LEW, Wei LIN, Jingchuan ZHANG, Joanne OH
  • Plasmids suitable for gene therapy
    Patent number: 5910488
    Abstract: The invention provides vectors adapted for use in transferring into tissue or cells of an organism genetic material encoding one or more cistrons capable of expressing one or more immunogenic or therapeutic peptides and related methods.
    Type: Grant
    Filed: December 1, 1995
    Date of Patent: June 8, 1999
    Assignee: Vical Incorporated
    Inventors: Gary J. Nabel, Elizabeth G. Nabel, Denise Lew, Magda Marquet